Dystonia Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

Description

List of Tables

The global dystonia drugs market was valued at $806.67 million in 2021, and is projected to reach $1,378.67 million by 2031, registering a CAGR of 5.5% from 2022 to 2031. Dystonia may be defined as a movement disorder which is characterized by involuntary contraction of the muscles which causes repetitive or twisting movements. This condition may affect a single (focal dystonia) or two parts (segmental dystonia) of the body or can affect the whole body of the patient which is termed as (general dystonia). These muscle contractions can be mild or severe in nature and can affect the movement of the person due to abnormal posture. Moreover, women are more prone to the condition than the men. Symptoms of dystonia include the cramping of the foot, involuntary pulling of the neck, uncontrollable blinking, speech difficulties and others. People also suffer from pain and discomfort as a result of constant muscle contractions. However, dystonia does not have a specific cause but is known to occur as a result of problems related to basal ganglia which leads to muscle contractions in the person.

Major approaches for treating dystonia include botulinum toxin (botox) injections, several drug types of medication and surgery. These approaches can be used individually or in combination for treating dystonia. In addition, the drugs used for the treatment of dystonia includes muscle relaxants, anticholinergic drugs, anticonvulsants, dopaminergic agents and others. The response to these medications depends on different individuals and may also differ according to the severity of the condition.

The major factor driving the growth of dystonia drugs market includes the increase in incidences of dystonia in developed and developing regions, along with increase in prevalence of conditions such as Parkinson's disease, Huntington's disease and others. For instance, according to The Parkinson's Foundation, nearly 90,000 people in the U.S. are diagnosed with Parkinson's disease each year and more than 10 million people worldwide are living with Parkinson's disease. As Parkison's disease and dystonia are closely related to each other, increase in prevalence of Parkinsons diseases increases the incidence of dystonia. This further increases the demand for dystonia treatment drugs and thus, propels the growth of dystonia drugs market.

In addition, major key players are offering a wide range of dystonia drug products with significant product differentiation. Manufacturers are focusing on developing novel formulations which are highly potent and effective and are easily accessible to the patients. Thus, increase in such product offering by the key market players is anticipated to increase the prescription of various dystonia medications by healthcare providers and patients and thereby augment the growth of the market.

Furthermore, the increase in funding and investment by the key market players in the developing regions is boosting the market growth. Regions such as Asia-Pacific have been the point of attraction for the investors owing to the presence of essential resources in this region. Moreover, Asia-Pacific is emerging as a pharmaceutical hub for supply of medications and devices around the globe. This also propels the growth dystonia drugs market.

Although various key factors are driving the growth of the market, there are few factors such as lack of awareness about the condition and its treatment options in underdeveloped countries is providing hindrance to the growth of the market. Dystonia is often left undiagnosed as people have less knowledge regarding the condition. Also, people in developing countries are unaware about the advanced treatment options available for dystonia. Also, availability of new alternate treatment options such as surgeries and other physical therapies, further acts as a restraint to the growth of the market.

The global dystonia drugs market is segmented on the basis of drug type, distribution channel and region. By drug type, the market is categorized into dopaminergic agents, GABAergic agents, anticonvulsants, and others. On the basis of route of administration, the market is segmented into oral and injection. Based on distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major Key players that operate in the global Dystonia Drugs Market are: AbbVie Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, Hameln Pharma GmbH, Ipsen Pharma, Merz Pharmaceuticals, LLC, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and Wellona Pharma.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dystonia drugs market analysis from 2021 to 2031 to identify the prevailing dystonia drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the dystonia drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global dystonia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

Anticonvulsants drugs
Others
Dopaminergic agents
GABAergic agents

By Route of Administration

Oral
Injectable

By Distribution Channel

Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players

Hameln Pharma Gmbh
Ipsen Pharma
Novartis AG
Pfizer Inc.
Wellona Pharma
Teva Pharmaceutical Industries Limited
Amneal Pharmaceuticals LLC
F. Hoffmann-La Roche Ltd.
Merz Pharmaceuticals, LLC
Abbvie Inc

Product Code: A13938

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate bargaining power of buyers
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate threat of new entrants
- 3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in R&D activities in pharmaceutical field
  - 3.4.1.2. Increase in incidences of dystonia
  - 3.4.1.3. Increase in prevalence of neurological disorders
- 3.4.2. Restraints
  - 3.4.2.1. Lack of awareness about dystonia in underdeveloped nations
- 3.4.3. Opportunities
  - 3.4.3.1. Growth opportunity in emerging markets
3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DYSTONIA DRUGS MARKET, BY DRUG TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Dopaminergic agents
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. GABAergic agents
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Anticonvulsants drugs
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Injectable
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: DYSTONIA DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug Type
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug Type
  - 7.2.5.1.3. Market size and forecast, by Route of Administration
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug Type
  - 7.2.5.2.3. Market size and forecast, by Route of Administration
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drug Type
  - 7.2.5.3.3. Market size and forecast, by Route of Administration
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug Type
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug Type
  - 7.3.5.1.3. Market size and forecast, by Route of Administration
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug Type
  - 7.3.5.2.3. Market size and forecast, by Route of Administration
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug Type
  - 7.3.5.3.3. Market size and forecast, by Route of Administration
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug Type
  - 7.3.5.4.3. Market size and forecast, by Route of Administration
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drug Type
  - 7.3.5.5.3. Market size and forecast, by Route of Administration
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drug Type
  - 7.3.5.6.3. Market size and forecast, by Route of Administration
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug Type
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug Type
  - 7.4.5.1.3. Market size and forecast, by Route of Administration
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug Type
  - 7.4.5.2.3. Market size and forecast, by Route of Administration
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug Type
  - 7.4.5.3.3. Market size and forecast, by Route of Administration
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. India
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drug Type
  - 7.4.5.4.3. Market size and forecast, by Route of Administration
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drug Type
  - 7.4.5.5.3. Market size and forecast, by Route of Administration
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drug Type
  - 7.4.5.6.3. Market size and forecast, by Route of Administration
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug Type
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug Type
  - 7.5.5.1.3. Market size and forecast, by Route of Administration
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug Type
  - 7.5.5.2.3. Market size and forecast, by Route of Administration
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Drug Type
  - 7.5.5.3.3. Market size and forecast, by Route of Administration
  - 7.5.5.3.4. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Drug Type
  - 7.5.5.4.3. Market size and forecast, by Route of Administration
  - 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Abbvie Inc
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. F. Hoffmann-La Roche Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Hameln Pharma Gmbh
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
9.4. Ipsen Pharma
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Merz Pharmaceuticals, LLC
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Key strategic moves and developments
9.6. Novartis AG
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Pfizer Inc.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Wellona Pharma
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
9.9. Teva Pharmaceutical Industries Limited
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Amneal Pharmaceuticals LLC
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments